SRP3182
VEGF human
Animal-component free, recombinant, expressed in E. coli, ≥98% (SDS-PAGE), ≥98% (HPLC), suitable for cell culture
Synonyme(s) :
Folliculostellate cell-derived growth factor, Glioma-derived endothelial cell mitogen, VPF, Vascular Endothelial Growth Factor-A
Se connecterpour consulter vos tarifs contractuels et ceux de votre entreprise/organisme
About This Item
Code UNSPSC :
12352202
Nomenclature NACRES :
NA.32
Produits recommandés
Source biologique
human
Produit recombinant
expressed in E. coli
Pureté
≥98% (HPLC)
≥98% (SDS-PAGE)
Forme
lyophilized
Puissance
1.0-8.0 ng/mL
Poids mol.
38.2 kDa
Conditionnement
pkg of 10 μg
Technique(s)
cell culture | mammalian: suitable
Impuretés
<0.1 EU/μg endotoxin, tested
Couleur
white
Numéro d'accès UniProt
Conditions d'expédition
wet ice
Température de stockage
−20°C
Informations sur le gène
human ... VEGFA(7422)
Description générale
VEGF (vascular endothelial growth factor) signals through the three receptors; fms-like tyrosine kinase (flt-1), KDR gene product (the murine homolog of KDR is the flk-1 gene product) and the flt4 gene product. Recombinant human VEGF is a 38.2kDa disulfide-linked homodimeric protein consisting of two 165 amino acid polypeptide chains.
Application
VEGF human has been used as a chemoattractant for HUVECs (human umbilical vein endothelial cells) migration assay.
Actions biochimiques/physiologiques
VEGF (vascular endothelial growth factor) is a potent growth and angiogenic cytokine. It stimulates proliferation and survival of endothelial cells, and promotes angiogenesis and vascular permeability. Expressed in vascularized tissues, VEGF plays a prominent role in normal and pathological angiogenesis. Substantial evidence implicates VEGF in the induction of tumor metastasis and intraocular neovascular syndromes. Polymorphism in VEGF at C(-634)G is linked with diabetic retinopathy in type 2 diabetes.
Séquence
APMAEGGGQN HHEVVKFMDV YQRSYCHPIE TLVDIFQEYP DEIEYIFKPS CVPLMRCGGC CNDEGLECVP TEESNITMQI MRIKPHQGQH IGEMSFLQHN KCECRPKKDR ARQENPCGPC SERRKHLFVQ DPQTCKCSCK NTDSRCKARQ LELNERTCRC DKPRR
Forme physique
Lyophilized with no additives.
Reconstitution
Centrifuge the vial prior to opening. Reconstitute in water to a concentration of 0.1-1.0 mg/ml. Do not vortex. This solution can be stored at 2-8°C for up to 1 week. For extended storage, it is recommended to further dilute in a buffer containing a stabilizer (example 5% Trehalose) and store in working aliquots at -20°C to -80°C.
Code de la classe de stockage
11 - Combustible Solids
Classe de danger pour l'eau (WGK)
WGK 3
Point d'éclair (°F)
Not applicable
Point d'éclair (°C)
Not applicable
Certificats d'analyse (COA)
Recherchez un Certificats d'analyse (COA) en saisissant le numéro de lot du produit. Les numéros de lot figurent sur l'étiquette du produit après les mots "Lot" ou "Batch".
Déjà en possession de ce produit ?
Retrouvez la documentation relative aux produits que vous avez récemment achetés dans la Bibliothèque de documents.
Les clients ont également consulté
Naoki Horikawa et al.
Clinical cancer research : an official journal of the American Association for Cancer Research, 23(2), 587-599 (2016-07-13)
High VEGF expression in ovarian cancer is an unfavorable prognostic factor. However, the role of VEGF in tumor immunity remains unclear. Here, we examined the impact of VEGF on local immunity, including induction of myeloid-derived suppressor cells (MDSC), in ovarian
Ca2+ influx through reverse mode Na+/Ca2+ exchange is critical for vascular endothelial growth factor-mediated extracellular signal-regulated kinase (ERK) 1/2 activation and angiogenic functions of human endothelial cells.
Andrikopoulos P
The Journal of Biological Chemistry, 286, 37919-37931 (2011)
Vegf, Vegf-B, Vegf-C and their receptors KDR, FLT-1 and FLT-4 during the neoplastic progression of human colonic mucosa.
Andre T
International Journal of Cancer. Journal International Du Cancer, 86, 174-181 (2000)
VEGF-A induces tumor and sentinel lymph node lymphangiogenesis and promotes lymphatic metastasis.
Hirakawa S
The Journal of Experimental Medicine, 20, 1089-1099 (2005)
M Clauss et al.
The Journal of experimental medicine, 172(6), 1535-1545 (1990-12-01)
Systemic infusion of low concentrations of tumor necrosis factor/cachectin (TNF) into mice that bear TNF-sensitive tumors leads to activation of coagulation, fibrin formation, and occlusive thrombosis exclusively within the tumor vascular bed. To identify mechanisms underlying the localization of this
Notre équipe de scientifiques dispose d'une expérience dans tous les secteurs de la recherche, notamment en sciences de la vie, science des matériaux, synthèse chimique, chromatographie, analyse et dans de nombreux autres domaines..
Contacter notre Service technique